Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Female%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
/vufind/Search/Results?lookfor=%22Female%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
Search /vufind/Search2/Results?lookfor=%22Female%22&type=Subject&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22
PubPharm (7.930)
1
A study to determine whether the addition of TSR-042, followed by the use of niraparib with TSR-042, delays recurrence of ovarian, primary peritoneal or fallopian tube cancer : A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer - The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR 042) Study
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
A phase 3 study to confirm the efficacy and safety of linzagolix to treat endometriosis-associated pain. : A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain. - Edelweiss 3
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Study of Letrozole Extension (SOLE) : A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer - Study of Letrozole Extension (SOLE)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME Investigator-initiierte einfach verblindete, zweiarmige, randomisierte klinische Phase 3 Studie zum Nachweis der Wirksamkeit auf das Haarvolumen von 5%igen Minoxidil 1x tgl. versus 2%igem Minoxidil 2x tgl. bei Frauen mit leichter bis mäßiger androgenetischer Alopezie : INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME Investigator-initiierte einfach verblindete, zweiarmige, randomisierte klinische Phase 3 Studie zum Nachweis der Wirksamkeit auf das Haarvolumen von 5%igen Minoxidil 1x tgl. versus 2%igem Minoxidil 2x tgl. bei Frauen mit leichter bis mäßiger androgenetischer Alopezie
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer : A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
A Clinical Trial for Newly Diagnosed High Risk Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer : A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL) - Nivo/Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in ER+/HER2-Breast Cancer
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
A STUDY COMPARING VLY-686 AND PLACEBO IN SUBJECTS WHO DO NOT RECEIVE RELIEF FROM CURRENT TREATMENT OPTIONS FOR ITCH ASSOCIATED WITH ATOPIC DERMATITIS. : A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT, ANTIPRURITIC STUDY OF THE NEUROKININ-1 RECEPTOR ANTAGONIST VLY-686 IN SUBJECTS WITH TREATMENT-RESISTANT PRURITUS ASSOCIATED WITH ATOPIC DERMATITIS
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
Benefit of treatment with a GnRH agonist (neurohormone) prior to frozen embryo transfer in patients with endometriosis (endometrial disease) and / or adenomyosis (another form of endometriosis) : Benefit of the GnRH agonist before frozen embryo transfer in patients with endometriosis and / or adenomyosis: randomized prospective study - DECATEC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
A randomised, multicentre, open-label, phase III study of neoadjuvantlapatinib, trastuzumab, and their combination plus paclitaxel in womenwith HER2/ErbB2 positive primary breast cancerNeo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study.Estudio fase III, aleatorizado, multicéntrico, abierto, de tratamiento neoadyuvante con lapatinib, trastuzumab y su combinación más paclitaxel en mujeres con cáncer de mama primario HER2/ErbB2 positivo.Estudio Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) - NeoALTTO : A randomised, multicentre, open-label, phase III study of neoadjuvantlapatinib, trastuzumab, and their combination plus paclitaxel in womenwith HER2/ErbB2 positive primary breast cancerNeo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study.Estudio fase III, aleatorizado, multicéntrico, abierto, de tratamiento neoadyuvante con lapatinib, trastuzumab y su combinación más paclitaxel en mujeres con cáncer de mama primario HER2/ErbB2 positivo.Estudio Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) - NeoALTTO
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
10
Study to allow access to imatinib for patients who are on imatinib treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by theinvestigator. : An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[793]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Medienart
7.930
Aufsätze
7.930
E-Artikel
7.930
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
7.930
610
7.444
Study Type: Interventional
3.510
Recruitment Status: Not yet recruiting
1.688
Recruitment Status: Completed
1.432
Phase: Phase 3
1.078
Recruitment Status: Authorised-recruitment may ...
944
Recruitment Status: Recruiting
922
Phase: Phase 2
482
Recruitment Status: Complete: follow-up complete
414
Study Type: Observational
398
Phase: Phase 4
246
Phase: Phase 2/Phase 3
218
Medical Condition: Healthy adult female
218
Phase: Phase 1
120
Medical Condition: Fertility-female;Fertility-f...
86
Medical Condition: Infertility. Female infertility
80
Phase: Phase 1/Phase 2
62
Medical Condition: Female infertility. Female i...
60
Medical Condition: Healthy male/female adults
60
Medical Condition: Infertility. Female infertil...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4.576
2020-
3.354
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
7.780
Englisch
92
Unbestimmt
16
Spanisch
12
Französisch
10
Niederländisch
8
Dänisch
4
Deutsch
2
Finnisch
2
Manx
2
Nyanja
2
Slowakisch
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...